Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 21,383 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer owned 761,550 shares of the company’s stock, valued at $3,183,279. This represents a 2.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Recursion Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ RXRX opened at $4.11 on Wednesday. The business has a fifty day moving average of $4.69 and a two-hundred day moving average of $5.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The stock has a market cap of $2.14 billion, a PE ratio of -2.28 and a beta of 0.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business’s revenue was down 80.1% on a year-over-year basis. During the same period last year, the firm posted ($0.34) EPS. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Finally, UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.50.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after purchasing an additional 4,149,346 shares during the last quarter. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth approximately $16,040,000. Advisors Asset Management Inc. increased its holdings in Recursion Pharmaceuticals by 753.8% in the first quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock valued at $706,000 after buying an additional 117,851 shares in the last quarter. Stratos Wealth Partners LTD. raised its holdings in Recursion Pharmaceuticals by 724.3% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company’s stock worth $499,000 after purchasing an additional 86,730 shares during the period. Finally, Ethic Inc. acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at $107,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.